Q1: A decent start to the year
13/05/22 -"Lundbeck has started the year on a decent note. While sales declined in constant currency terms, this had largely been expected due to Northera’s patent expiry. Encouragingly, substantial growth ..."
Pages
55
Language
English
Published on
13/05/22
You may also be interested by these reports :
25/05/22
Considering the group was already facing multiple headwinds – deteriorating generics pricing environment in the US, market share losses for its ...
18/05/22
We have updated our model to incorporate the impact of the spin-off of the API (active pharmaceutical ingredient) business, which had listed ...
18/05/22
Given the sustained recovery in the plasma supply – now back to pre-pandemic levels – Grifols has been benefiting from a recovery in investor ...
17/05/22
As Sensei has prioritised development of SNS-101 over the SNS-401-NG programme – possibly to manage cash burn, considering the recent decline in ...